|61.60||+0.5100||+0.83%||Vol 4.84M||1Y Perf -11.18%|
|Aug 8th, 2022 16:00 DELAYED|
|- -||0.02 0.03%|
|Target Price||72.71||Analyst Rating||Moderate Buy 2.35|
|Potential %||18.04||Finscreener Ranking||★★+ 46.85|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★+ 48.51|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★★ 58.08|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||★★★ 45.58|
|Price Range Ratio 52W %||26.16||Earnings Rating||Neutral|
|Market Cap||77.27B||Earnings Date||2nd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.51|
|EPS Growth Next 5 Years %||15.00|
|Avg. Weekly Volume||6.76M|
|Avg. Monthly Volume||5.93M|
|Avg. Quarterly Volume||6.84M|
Gilead Sciences Inc. (NASDAQ: GILD) stock closed at 61.6 per share at the end of the most recent trading day (a 0.83% change compared to the prior day closing price) with a volume of 4.84M shares and market capitalization of 77.27B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11800 people. Gilead Sciences Inc. CEO is Daniel O'Day.
The one-year performance of Gilead Sciences Inc. stock is -11.18%, while year-to-date (YTD) performance is -15.16%. GILD stock has a five-year performance of -16.64%. Its 52-week range is between 57.165 and 74.12, which gives GILD stock a 52-week price range ratio of 26.16%
Gilead Sciences Inc. currently has a PE ratio of 17.50, a price-to-book (PB) ratio of 3.94, a price-to-sale (PS) ratio of 3.59, a price to cashflow ratio of 7.40, a PEG ratio of 2.32, a ROA of 7.12%, a ROC of 11.06% and a ROE of 23.87%. The company’s profit margin is 14.15%, its EBITDA margin is 32.60%, and its revenue ttm is $21.26 Billion , which makes it $16.95 revenue per share.
Of the last four earnings reports from Gilead Sciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.51 for the next earnings report. Gilead Sciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Gilead Sciences Inc. is Moderate Buy (2.35), with a target price of $72.71, which is +18.04% compared to the current price. The earnings rating for Gilead Sciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Gilead Sciences Inc. has a dividend yield of 4.79% with a dividend per share of $2.92 and a payout ratio of 67.00%.
Gilead Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.58, ATR14 : 1.39, CCI20 : -9.54, Chaikin Money Flow : -0.08, MACD : -0.23, Money Flow Index : 30.12, ROC : -0.75, RSI : 45.03, STOCH (14,3) : 41.55, STOCH RSI : 0.68, UO : 46.02, Williams %R : -58.45), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Gilead Sciences Inc. in the last 12-months were: Andrew D. Dickinson (Option Excercise at a value of $0), Andrew Dickinson (Option Excercise at a value of $0), Anthony Welters (Option Excercise at a value of $0), Brett A. Pletcher (Option Excercise at a value of $0), Brett A. Pletcher (Sold 19 386 shares of value $1 283 364 ), Daniel O'Day (Option Excercise at a value of $0), Diane E. Wilfong (Option Excercise at a value of $926 536), Diane E. Wilfong (Sold 13 610 shares of value $986 725 ), Harish Manwani (Option Excercise at a value of $0), Jacqueline K. Barton (Option Excercise at a value of $0), Javier J. Rodriguez (Option Excercise at a value of $0), Jeffrey A. Bluestone (Option Excercise at a value of $0), Jeffrey Bluestone (Option Excercise at a value of $0), Johanna Mercier (Option Excercise at a value of $0), Kevin E. Lofton (Option Excercise at a value of $418 251), Merdad Parsey (Option Excercise at a value of $0), Merdad V. Parsey (Option Excercise at a value of $0), Sandra J. Horning (Option Excercise at a value of $0)
Tue, 07 Jun 2022 13:05 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and PDS Biotechnology (PDSB)- TipRanks. All rights reserved.
Thu, 12 May 2022 16:39 GMT Gilead Sciences (GILD) Gets a Buy Rating from Mizuho Securities- TipRanks. All rights reserved.
Tue, 03 May 2022 15:15 GMT Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Kymera Therapeutics (KYMR)- TipRanks. All rights reserved.
Fri, 29 Apr 2022 10:35 GMT Gilead Sciences (GILD) Receives a Hold from Needham- TipRanks. All rights reserved.
Tue, 12 Apr 2022 15:55 GMT Can Gilead Stock Gain Traction Following FDA Lifting Partial Hold- TipRanks. All rights reserved.
Tue, 12 Apr 2022 13:04 GMT Gilead Sciences (GILD) Receives a Buy from RBC Capital- TipRanks. All rights reserved.
Fri, 08 Apr 2022 01:51 GMT Gilead Sciences (GILD) Gets a Buy Rating from RBC Capital- TipRanks. All rights reserved.
Fri, 01 Apr 2022 02:36 GMT Gilead Sciences (GILD) Gets a Hold Rating from Robert W. Baird- TipRanks. All rights reserved.
Thu, 27 Jan 2022 07:55 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Catalent (CTLT)- TipRanks. All rights reserved.
Tue, 18 Jan 2022 16:36 GMT Gilead Sciences (GILD) Receives a Hold from Morgan Stanley- TipRanks. All rights reserved.
Fri, 14 Jan 2022 13:06 GMT Gilead Sciences (GILD) Receives a Buy from Jefferies- TipRanks. All rights reserved.
Mon, 10 Jan 2022 19:30 GMT Gilead Sciences: Attractive Dividend Yield and Improving Financials- TipRanks. All rights reserved.
Fri, 07 Jan 2022 01:47 GMT RBC Capital Believes Gilead Sciences (GILD) Still Has Room to Grow- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.